129 related articles for article (PubMed ID: 1523880)
1. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.
Costantino P; Viti S; Podda A; Velmonte MA; Nencioni L; Rappuoli R
Vaccine; 1992; 10(10):691-8. PubMed ID: 1523880
[TBL] [Abstract][Full Text] [Related]
2. Efficient solid-phase synthesis of meningococcal capsular oligosaccharides enables simple and fast chemoenzymatic vaccine production.
Fiebig T; Litschko C; Freiberger F; Bethe A; Berger M; Gerardy-Schahn R
J Biol Chem; 2018 Jan; 293(3):953-962. PubMed ID: 29187601
[No Abstract] [Full Text] [Related]
3. Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.
Verheul AF; Braat AK; Leenhouts JM; Hoogerhout P; Poolman JT; Snippe H; Verhoef J
Infect Immun; 1991 Mar; 59(3):843-51. PubMed ID: 1900063
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults.
Deeks ED
BioDrugs; 2010 Oct; 24(5):287-97. PubMed ID: 20795751
[TBL] [Abstract][Full Text] [Related]
6. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.
Cox AD; Zou W; Gidney MA; Lacelle S; Plested JS; Makepeace K; Wright JC; Coull PA; Moxon ER; Richards JC
Vaccine; 2005 Oct; 23(43):5045-54. PubMed ID: 16046037
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.
Bartoloni A; Norelli F; Ceccarini C; Rappuoli R; Costantino P
Vaccine; 1995 Apr; 13(5):463-70. PubMed ID: 7543714
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the non-toxic mutant of the diphtheria toxin K51E/E148K as carrier protein for meningococcal vaccines.
Pecetta S; Vijayakrishnan B; Romano MR; Proietti D; Lo Surdo P; Balocchi C; Mori E; Davis BG; Berti F
Vaccine; 2016 Mar; 34(11):1405-11. PubMed ID: 26845738
[TBL] [Abstract][Full Text] [Related]
9. Preclinical studies on new proteins as carrier for glycoconjugate vaccines.
Tontini M; Romano MR; Proietti D; Balducci E; Micoli F; Balocchi C; Santini L; Masignani V; Berti F; Costantino P
Vaccine; 2016 Jul; 34(35):4235-4242. PubMed ID: 27317455
[TBL] [Abstract][Full Text] [Related]
10. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.
Baraldo K; Mori E; Bartoloni A; Norelli F; Grandi G; Rappuoli R; Finco O; Del Giudice G
Infect Immun; 2005 Sep; 73(9):5835-41. PubMed ID: 16113302
[TBL] [Abstract][Full Text] [Related]
11. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.
MacLennan JM; Shackley F; Heath PT; Deeks JJ; Flamank C; Herbert M; Griffiths H; Hatzmann E; Goilav C; Moxon ER
JAMA; 2000 Jun; 283(21):2795-801. PubMed ID: 10838647
[TBL] [Abstract][Full Text] [Related]
14. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135.
Bardotti A; Averani G; Berti F; Berti S; Galli C; Giannini S; Fabbri B; Proietti D; Ravenscroft N; Ricci S
Vaccine; 2005 Mar; 23(16):1887-99. PubMed ID: 15734061
[TBL] [Abstract][Full Text] [Related]
15. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis.
Pon RA; Lussier M; Yang QL; Jennings HJ
J Exp Med; 1997 Jun; 185(11):1929-38. PubMed ID: 9166422
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.
Tontini M; Berti F; Romano MR; Proietti D; Zambonelli C; Bottomley MJ; De Gregorio E; Del Giudice G; Rappuoli R; Costantino P; ; Brogioni G; Balocchi C; Biancucci M; Malito E
Vaccine; 2013 Oct; 31(42):4827-33. PubMed ID: 23965218
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
[TBL] [Abstract][Full Text] [Related]
19. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
Beresford NJ; Martino A; Feavers IM; Corbel MJ; Bai X; Borrow R; Bolgiano B
Vaccine; 2017 Jun; 35(28):3598-3606. PubMed ID: 28408122
[TBL] [Abstract][Full Text] [Related]
20. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.
Santosham M; Wolff M; Reid R; Hohenboken M; Bateman M; Goepp J; Cortese M; Sack D; Hill J; Newcomer W
N Engl J Med; 1991 Jun; 324(25):1767-72. PubMed ID: 1903846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
